Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is
the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is …

The diagnostic assessment of liver injury is an important step in the management of patients
with chronic liver disease (CLD). Although liver biopsy is the reference standard for the …

Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

Background & Aims Previous studies on the prognostic significance of non-invasive liver
fibrosis tests in non-alcoholic fatty liver disease (NAFLD) lack direct comparison to liver …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying
advanced fibrosis caused by nonalcoholic steatohepatitis (NASH). We analyzed screening …

Chronic liver disease (CLD) leads to liver fibrosis; it is associated with approximately two
million annual deaths worldwide and is an enormous health burden.[1, 2] The majority of …

Two‐dimensional shear wave elastography (2D‐SWE) has proven to be efficient for the
evaluation of liver fibrosis in small to moderate‐sized clinical trials. We aimed at running a …

Liver fibrosis is part of the structural and functional alterations in most chronic liver diseases.
It is one of the main prognostic factors as the amount of fibrosis is correlated with the risk of …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in
affluent countries. Accurate noninvasive tests for liver injury are urgently needed. The aim of …